Clinical Trial Update: Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

View source ↗

Summary

A clinical trial is evaluating Zn-DDC to target the Hypoxia-NFkappaB-CSCs pathway in multiple myeloma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Zn-DDC

Snippet

Sponsor: The Royal Wolverhampton Hospitals NHS Trust | Conditions: Multiple Myeloma | Status: RECRUITING